Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

Saved in:

Bibliographic Details
Main Authors:	NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto
Format:	Article
Language:	English
Published:	PAGEPress Publications 2022-06-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Online Access:	https://www.mjhid.org/index.php/mjhid/article/view/4990
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

“Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency.
by: NICOLA SGHERZA, et al.
Published: (2020-10-01)

Toxoplasmosis in thalassemic Iraqi patients: serological and hematological study
by: Raghad N. Shihab, et al.
Published: (2024-06-01)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023-07-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function.
by: Takayuki Yamaji, et al.
Published: (2024-01-01)

Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
by: Ho Yu Ng, et al.
Published: (2025-02-01)

Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
by: Aisling R. Caffrey, et al.
Published: (2024-11-01)

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
by: Kayvon Modjarrad, et al.
Published: (2024-11-01)

Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
by: Claudio Ucciferri, et al.
Published: (2022-02-01)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
by: Sho Iketani, et al.
Published: (2021-01-01)

Coagulation defects in thalassemic patients
by: Mostafa M. Abosdera, et al.
Published: (2017-10-01)

Elevated alanine transaminase in liver transplant recipients after BNT162b2 vaccination: a cohort study
by: Jacob Siewertsen Bergmann, et al.
Published: (2025-08-01)

Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine
by: Sydney Ann Kee, PhD, et al.
Published: (2025-08-01)

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
by: Younes Bathish, et al.
Published: (2024-12-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
by: Lilia M. Sierra Galan, et al.
Published: (2025-01-01)

BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
by: Chen-Wei Yen, et al.
Published: (2023-11-01)

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
by: Frank van den Ouweland, et al.
Published: (2024-12-01)

Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer
by: K.L. Juliëtte Schmidt, et al.
Published: (2024-12-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
by: Masliyana Husin, et al.
Published: (2025-01-01)

Determination of Quality of Life for Thalassemic Adolescent
by: Kafi Mohammed Nasir, et al.
Published: (2013-08-01)

Comparative Analysis of Craniofacial Parameters in Thalassemic Patients and Non-Thalassemic Individuals across Both Sexes in Chattogram, Bangladesh
by: Sabrina Tasnim, et al.
Published: (2025-04-01)

Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty
by: Kuang-Jen Chien, et al.
Published: (2023-05-01)

Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescentsResearch in context
by: Qiong Wu, et al.
Published: (2025-01-01)

Allergy to PEG (polyethylene glycol) – sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024-12-01)

Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System
by: Haley J. Appaneal, et al.
Published: (2025-04-01)

Relapse of Evans syndrome following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine: case report and literature review
by: Mirjana Cvetković, et al.
Published: (2023-06-01)

Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain
by: Luis Sarabia de Ardanaz, et al.
Published: (2025-05-01)

Occult hepatitis B in Egyptian thalassemic children
by: Olfat Shaker, et al.
Published: (2011-07-01)

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
by: William N Whiteley, et al.
Published: (2022-02-01)

A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”
by: Timothy E. Albertson, et al.
Published: (2025-04-01)

Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
by: Anja Rosdahl, et al.
Published: (2024-12-01)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution
by: Andreina Baj, et al.
Published: (2021-01-01)

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data.
by: Lilac Tene, et al.
Published: (2023-01-01)

Löfgren’s Syndrome Following BNT162b2 mRNA COVID-19 Vaccination and Subsequent Plaque-type Cutaneous Sarcoidosis after its Resolution
by: Masahiro Oka, et al.
Published: (2025-06-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

Effect of recent SARS-CoV-2 infection on anti-spike protein immunoglobulin G II response after BNT162b2 vaccination
by: Daiki Tanno, et al.
Published: (2025-08-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)